Neurology specialty drugs are expected to increase hospital pharmaceutical spend by 3.42 percent in 2024, according to a Vizient analysis. Three of the five most expensive drugs used by Vizient’s clients are specialty drugs — Humira (adalimumab), Stelara (ustekinumab), and Prolia and Xgeva denosumab (denosumab) — and two neurology drugs recently broke into the top […]
